pre-IPO PHARMA

COMPANY OVERVIEW

Ribometrix is a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases. The Ribometrix team leverages its world-leading expertise in 3D structural analysis of RNA to drive its discovery platform, drawing on technologies invented in the laboratory of Ribometrix scientific founder Kevin Weeks, Ph.D. Ribometrix is headquartered in Durham, North Carolina.


LOCATION

  • Durham, NC, USA

  • THERAPEUTIC AREAS


    WEBSITE

    https://www.ribometrix.com


    CAREER WEBSITE

    https://www.ribometrix.com/careers.html


    SOCIAL MEDIA


    INVESTORS

    abbvie-ventures alexandria-venture-investments amgen-ventures dementia-discovery-fund hatteras-venture-partners illumina-ventures m-ventures mp-healthcare-venture-management pappas-capital sv-health-investors


    PRESS RELEASES


    Mar 21, 2022

    Ribometrix Promotes Dr. Manjunath Ramarao to Chief Scientific Officer


    Jun 28, 2021

    Ribometrix Appoints Dr. Manjunath Ramarao as Senior Vice President of Research


    May 20, 2021

    Ribometrix Wins Triangle Business Journal’s “Best Early-Stage Product Development Company” Award


    Jan 6, 2021

    Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics


    Aug 4, 2020

    Ribometrix Further Expands Leadership with Appointment of Barclay “Buck” Phillips as Chief Operating Officer and Chief Financial Officer


    For More Press Releases


    Google Analytics Alternative